Enzyme replacement therapy leading to improvement in myeloma indices in a patient with concomitant Gaucher disease

Intern Med J. 2022 May;52(5):872-875. doi: 10.1111/imj.15781.

Abstract

Patients with Gaucher disease (GD) have been shown previously to carry an increased risk for cancer, most commonly multiple myeloma (MM). It is currently unknown whether treatment for GD has an effect on the prevention or amelioration of MM. We present the case of a 41-year-old patient simultaneously diagnosed with GD and smouldering MM. Enzyme replacement therapy with Velaglucerase-alfa significantly improved myeloma indices.

Keywords: Gaucher disease; enzyme replacement therapy; monoclonal gammopathy of unknown significance (MGUS); multiple myeloma; polyclonal gammopathy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Enzyme Replacement Therapy
  • Gaucher Disease* / complications
  • Gaucher Disease* / drug therapy
  • Glucosylceramidase / therapeutic use
  • Humans
  • Multiple Myeloma* / complications
  • Multiple Myeloma* / diagnosis
  • Multiple Myeloma* / drug therapy

Substances

  • Glucosylceramidase